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Introduction
Clostridium difficile is an anaerobic spore forming grampositive bacillus. It constitutes part of normal intestinal flora in 1-3 per cent of adults and 15-20 per cent of infants. 1 It is known to cause potentially lethal infections in both hospitalised and community patients, especially those receiving broad-spectrum antimicrobials. The incidence of C. difficile infection (CDI) varies from 45.7 to 155.9/100,000 in healthcare facilities. 2 Evidences suggest the epidemiology of CDI has changed significantly over decades. 1 Until recently, it was primarily nosocomial in nature. However, several community-acquired cases have been recently reported. The incidence of community-acquired CDI (CA-CDI) has shown an increasing trend, accounting for about 32
per cent of CDI cases in the United States. 2 Furthermore, occurrence of CDI has become frequent among low-risk groups (i.e., children and peripartum women). 1, 3 The worldwide increase in the incidence of CDI in recent years is attributed to excessive usage of antibiotics and proton pump inhibitors, increased incidence of inflammatory bowel disease, and growing numbers of elderly people in assisted
What is known about this subject?
Clostridium difficile has been increasingly reported worldwide as a cause of infectious diarrhoea in patients with prolonged hospital stay. Metronidazole and oral vancomycin are the most widely used antibiotics for its treatment.
living facilities and nursing homes. Pseudomembranous colitis, fulminant colitis, toxic megacolon and bowel infarction are the common complications. 1 Bacterial translocation associated with bowel inflammation, infarction, and perforation often results in sepsis, systemic inflammatory response syndrome, hypotension, and renal failure. 1 Antibiotics are the mainstay of non-surgical treatment for primary and recurrent CDI. The emergence of hypervirulent strains and the risk of drug resistance among C. difficile is now a growing concern among clinicians. 1 Resistance to metronidazole and reduced susceptibility to vancomycin have been reported. 4 Also, antibiotic selection is further complicated by the risk of dissemination of vancomycin resistance among Enterococcus spp. 1, 5 There is an increasing need and interest to counter these by developing novel therapeutic modalities. Among the newer drugs under development, cadazolid has shown initial promising results.
Here, cadazolid as a prospective medical therapy for CDI is discussed in light of current clinical and experimental evidence.
Clostridium difficile infections CDI is acquired either as an endogenous (caused by carrier strains) or exogenous infection (from nosocomial sources). The ingested spores of C. difficile survive in gastric acid and germinate in the intestine. Altered intestinal microflora associated with medical therapy promote its colonisation, proliferation, and toxin production resulting in a carrier state, diarrhoea (C. difficile-associated diarrhoea), or colitis (C. difficile-associated colitis, pseudomembranous colitis, fulminant colitis). 9 Recently, heteroresistance to metronidazole has been described, which may explain its incomplete therapeutic response in CDI cases. 10 Although the MICs for vancomycin in most studies were in the sensitive range, C. difficile isolates with reduced susceptibility to vancomycin have also been reported. 4 Oral (or rectal enema) vancomycin using a tapered or pulse regimen is preferred in severe or recurrent CDI. Owing to the high concentration achieved in faeces with enteral vancomycin therapy, resistance development is unlikely to be a concern. However, it is more likely to disseminate vancomycin resistance among Enterococcus spp. 
Cadazolid molecular structure
Oxazolidinone antibiotics characteristically contain 2-oxazolidone, an organic heterocyclic compound possessing a 5-membered ring. 14 Although cycloserine was the first member of this class, it has limited utility as an antibiotic (except for tuberculosis). In contrast, linezolid rapidly emerged as a popular oxazolidinone antibiotic, effective against multi-resistant, gram-positive bacteria. Cadazolid, eperezolid, tedizolid, radezolid, and posizolid are other members of this class. 14 The chemical structure of cadazolid
indicates that it is a hybrid antibiotic containing a quinonolone pharmacophore incorporated in an oxazolidinone ring. 15 It has a 6-fluoro group in the heterobicyclic quinolone nucleus similar to that of fluoroquinolone derivatives. The quinolone pharmacophore of cadazolid contributes to bacterial DNA synthesis inhibition. 14, 15 Cadazolid is acidic and lipophilic in nature with poor solubility in aqueous solutions. 16 Consequently, its systemic bioavailability is negligible, as the absorption from intestine following oral administration is minimal. 17 The promising results of phase I and phase II studies support its priority on development.
History of development

Mechanisms of action
Protein synthesis inhibition is the main antibacterial action exerted by cadazolid. In addition, it weakly inhibits bacterial DNA synthesis. Locher et al. carried out a series of in-vitro tests to study the mechanism of action of cadazolid. 19 Using a macromolecular labelling assay, the site of action of cadazolid in the bacterial cell was investigated by monitoring its inhibitory action on incorporation of labelled macromolecules; i.e., L-leucine (protein synthesis), adenine (nucleic acid synthesis), and N-acetyl-D-glucosamine (cell wall synthesis). Also, its influence on transcription and translation was determined by cell-free coupled transcription/translation assays (CFTA) and on DNA supercoiling and decatenation by DNA topoisomerase assays. It was found that cadazolid displayed potent protein synthesis inhibition when compared with DNA synthesis inhibition in both quinolone-resistant and linezolid-resistant C. difficile strains. 19 Cadazolid inhibited in-vitro translation in CFTA with potency much superior to linezolid. It showed demonstrable inhibition of E. coli DNA gyrase and topoisomerase IV. However, it failed to show measurable inhibition of C. difficile DNA gyrase. On antibiotic susceptibility tests, C. difficile strains had much lower MIC (0.125 to 0.5 µg/ml) for cadazolid when compared with other antibiotics. 15 The potency of cadazolid was higher than that of linezolid (8-to 64-fold), ciprofloxacin (64-fold), and moxifloxacin (8-to 64-fold). Nosocomial outbreaks of CDI with increase in mortality, relapses, complications intensive care admission, and surgical intervention have been reported from Canada, the United States, and several European countries in the last decade. 7, 8 The majority of the C. difficile isolates associated with these outbreaks belonged to ribotype 027 and toxinotype III. This new strain characteristically displayed enhanced production of toxin A and toxin B associated with tcdC gene mutation. High-level fluoroquinolone resistance has been frequently reported. 8 Multilocus variable-number tandem repeat analyses (MLVA), microarray analyses, restriction endonuclease analyses (REA), pulsed-field gel electrophoresis, toxin gene polymorphism typing, and ribotyping were used extensively for typing and this emerging strain was designated as BI/NAP1/027. 1 The superior antimicrobial activity of cadazolid was also demonstrated in time kill assays. They showed more than a 3 x log10 CFU reduction within 24 hours for wild strains as well as hypervirulent and quinoloneresistant strains. In contrast, in the case of vancomycin the initial rate of killing was slow and 3 x log10CFU reduction was not achieved. 15 Cadazolid showed potent biological effects on C. difficile toxin and spore formation. 15 Inhibition of toxin production was reported even at a lower concentration (0.25xMIC) and reached maximum potency at 1x and 4xMIC concentration. In contrast, only 4xMIC concentration of linezolid was inhibitory to C. difficile toxin, while other anti-C. difficile antibiotics showed no effect. Interestingly, moxifloxacin and vancomycin were found to increase toxin formation at sub-MIC concentration. While vancomycin at 0.5 and 1xMIC concentration failed to inhibit or delay spore formation, cadazolid markedly inhibited sporulation at sub-growthinhibitory (0.5xMIC) concentrations and delayed new spore formation for up to five days at 1xMIC.
Effect on intestinal microbiota
Chilton et al. studied the interplay between antibiotics, intestinal microflora, and C. difficile using a triple-stage chemostat-based human gut model. 20 The chemostat was inoculated with C. difficile-negative pooled faecal samples. On reaching the steady-state of microbial population, the system was inoculated with 10 7 CFU spores of C. difficile and was exposed to clindamycin to simulate the intestinal microenvironment as in CDI. Once C. difficile toxin production was high, cadazolid was instilled for seven days at high-and low-dose regimens (250 mg/L or 750 mg/L twice daily). Cadazolid concentration and cytotoxin titres were monitored for 14 days. It was found that cadazolid maintained a high concentration (50-100-fold supra-MIC) for 14 days post-dosing, which resulted in rapid reduction of viable counts of C. difficile and cytotoxin titres. Although Bifidobacterium counts decreased, other beneficial gut flora remained unaffected. 20 Furthermore, there was no evidence of repopulation (recurrence) of C. difficile in this experiment.
Propensity to develop resistance
The major concern limiting the therapeutic prospect of an antibiotic is its tendency to induce resistance among pathogenic microbes with continuous use. 
Therapeutic efficacy, safety and tolerability
The pharmacokinetic profile and safety of cadazolid have been investigated in animal studies and human clinical trials. In one animal study, cadazolid was found to substantially prevent mortality and diarrhoea associated with CDI in mice and hamsters in a dose-dependent manner in comparison to the control animals. 15 However, the results were found more reproducible in mice experiments than in hamsters. There was significant reduction in the risk of death in mice by 56, 96, and 95 per cent at 0.1, 1, and 10 mg/kg doses, respectively, during the monitoring period of 18 days. 15 Although the overall rates of survival were comparable to vancomycin at the same doses, cadazolid decreased risk of death in infected mice during the monitoring period of 18 days indicating its sustained treatment effect.
Currently, there are six clinical trials for cadazolid ( Table 1) . Out of these, four are also registered in the US Clinical trials registry. [21] [22] [23] [24] The results of phase I clinical trials evaluating the tolerability and pharmacokinetics of cadazolid following single ascending doses (SAD) and multiple ascending doses (MAD) are now available. 16 The results of phase III studies are yet to be published.
In a phase I study, oral doses of cadazolid between 30mg and 3,000 mg were tested in a total of 64 healthy male subjects and cadazolid was well tolerated up to 3,000mg twice daily for 10 days. In a SAD study, 40 subjects were selected into five treatment groups consisting of eight subjects each, for administering a single dose of cadazolid of 30mg, 100mg, 300mg, 1,000mg, and 3,000mg, respectively. 16 In each group, six subjects received cadazolid and the remaining two received a placebo. Likewise, the MAD study had three treatment groups (300mg, 1,000mg, and 3,000mg) of eight subjects, of which six in each group were administered with oral cadazolid twice daily for 10 days. 16 Headache and diarrhoea were the commonest adverse effects. Three out of 40 participants reported diarrhoea in the SAD study and one had loss of appetite in the MAD study. No dose-limiting adverse reaction was noted. The low plasma concentration of cadazolid (3.3 to 6.9ng/ml) is attributed to its poor intestinal absorption and consequently, its pharmacokinetic properties were detected only in the higher single dose groups and in all multiple dose groups on the 10th day. The mean t1/2 in 300mg, 1,000mg, and 3,000mg SAD treatment groups were 2.85, 3.58, and 12.85 hours, respectively. Although food was found to increase the rate of absorption (t1/2 in 300mg group in fed state was 6.5 hours), plasma levels remained low. After a single dose of 30, 100, 300, or 1,000mg, cadazolid remained detectable in plasma for two, four, six, and eight hours, respectively. 11 With multiple doses, plasma levels reached steady state after 3-4 days. The mean t1/2 in 300mg, 1,000mg, and 3,000 mg MAD treatment groups on the 10th day were 14.04, 14.19, and 13.02 hours respectively. The antibiotic showed biphasic elimination with a slow second phase from eight hours post-dose. Cadazolid was found to have predominant faecal excretion (81-93.5 per cent) in unchanged form. The faecal recovery of unchanged drug was highest at 24 hours post-dose. Only a minor fraction of administered dose (<0.015 per cent) was recovered from the urine.
A multi-centre, double-blind, randomised phase II clinical trial was conducted to evaluate the efficacy, safety, and tolerability of 10-day, twice daily oral cadazolid therapy in 84 CDI patients. 21, 25 However, unlike the phase I study, here 250mg, 500mg, or 1,000mg doses were evaluated in three treatment groups. Cadazolid was comparable or superior to vancomycin for the key endpoints (i.e., clinical cure rates and sustained cure rates) with lower recurrence rates for all three doses. Currently, two phase III clinical trials (NCT01987895 and NCT01983683) under an IMPACT program are in the recruiting phase. Approximately 1,280 subjects worldwide are expected to enrol for these studies.
25
Future prospects
It is evident from the currently available data that cadazolid is one of the promising future treatment options for CDI. Its low plasma concentration and narrow antimicrobial spectrum of activity precludes its wider use in systemic and polymicrobial infections. This selective distribution of cadazolid increases its bioavailability at the site of CDI. Since the liver and kidneys have a minimal role in its metabolism and excretion, cadazolid may be safer than other antibiotics in patients with decreased hepatic and renal functions. 16 Furthermore, its antimicrobial action on C. difficile without adversely affecting normal intestinal microbiota is a considerable advantage over several other antibiotics. 20 C.
difficile cytotoxins have an essential role in pathogenesis, whereas its spores are considered responsible for high recurrence rates. 15, 26 Unlike other antibiotics used in CDI, cadazolid substantially inhibits toxin production and sporulation even at low (sub-MIC) concentration. 15 Consequently, it is likely to prevent recurrent CDI more effectively. Its novel molecular structure, dual mechanism of action (strong inhibition of protein synthesis and weak inhibition of DNA synthesis) and lower propensity to develop resistance are other potential advantages. However, there are certain aspects of cadazolid that are yet to be explored. There are no data concerning its use in CDI patients with extraintestinal lesions; it is unlikely to be effective in extraintestinal CDI. Also, its teratogenic potential is unknown. Intestinal inflammation is a common feature of CDI and it may affect the absorption of cadazolid. Hence, there is a need to study its absorption from the inflamed gut and consequent plasma concentrations in human patients to standardise therapeutic regimens.
Conclusion
Cadazolid is a novel hybrid of oxazolidinone and quinolone antibiotics. It was found to have potent antimicrobial action for C. difficile without the major limitations (i.e., high recurrence, risk of resistance development, and intestinal dysbiosis) of antibiotics currently in use for CDI. With further clinical development cadazolid and other compounds of this class may emerge as primary therapeutic choices for CDI in near future. However, further studies are essential to define its clinical utility. 
